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Summary The levels of CA 242, a new tumour marker of carbohydrate nature, were measured in sera of 185
patients with malignancies of the digestive tract and of 123 patients with benign digestive tract diseases. High
percentages of elevated CA 242 levels (>20 U ml-') were recorded in patients with pancreatic and biliary
cancers (68%). The sensitivity was somewhat lower than that of CA 19-9 (76%) and CA 50 (73%). On the
other hand, in benign pancreactic and biliary tract diseases the CA 242 level was less frequently elevated than
the CA 19-9 and CA 50 levels. The serum CA 242 concentration was increased in 55% of patients with
colorectal cancer. CA 242 detected more Dukes A-B carcinomas (47%) than CEA (32%), whereas CEA was
more often elevated (71% vs 59%) in Dukes C-D carcinomas. CA 242 was slightly elevated (ad 41 U ml-') in
10% of patients with benign colorectal diseases. CA 50 and CA 19-9 had lower sensitivities than CA 242 using
the recommended cut-off values. When cut-off levels based on relevant benign colorectal diseases were used,
the sensitivities of these markers were similar and somewhat higher than that of CEA. Less than half of
patients with gastric cancer (44%) had an elevated CA 242 serum level. CA 242 is a promising new tumour
marker, that may be of additional value in the diagnosis of pancreatic and biliary, as well as colorectal cancer,
and may be useful in monitoring cancer patients after radical surgery.
Utilising hybridoma technology two new tumour markers,
CA 19-9 and CA 50, have recently been developed for the
diagnosis of digestive tract malignancies. The antibodies used
in these tests have been obtained by immunising mice with
two different human colorectal carcinoma cell lines (Koprow-
ski et al., 1979; Lindholm et al., 1983). The antigenic
determinant of CA 19-9 is sialylated Lewisa-blood group
substance (sialosyl-fucosyl-lactotetraose) (Magnani et al.,
1982) and that of CA 50, both the former structure, and also
sialosyl-lactotetraose, which lacks the fucosyl residue of the
sialylated Lewisa-antigen (Mansson et al., 1985; Nilsson et
al., 1985). Both epitopes are expressed on cell surfaces as
glycolipids and glycoproteins. In patients with digestive tract
malignancies, the antigens are also found in serum where
they are associated with a high molecular weight carbohy-
drate rich mucin fraction (Magnani et al., 1982; Lindholm et
al., 1983).
The highest frequency of elevated serum CA 19-9 and CA
50 levels are found in samples from patients with pancreatic
cancer, 71-92% of whom are reported to have elevated
marker values (DelVillano et al., 1983; Schmiegel et al., 1985;
Habib et al., 1986; Haglund et al., 1986; Steinberg et al.,
1986; Blind et al., 1987; Haglund et al., 1987; Kuusela et al.,
1987). High proportions of increased concentrations are also
found in patients with colorectal and biliary tract cancers
(Jalanko et al., 1984; Kuusela et al., 1984; Bruhn et al., 1985;
Paganuzzi et al., 1985; Kuusela et al., 1987). The drawback
of both tests are the findings that clearly elevated levels
mainly are found in patients with advanced disease, which
can rather easily be diagnosed also by other clinical and
laboratory criteria. In these patients the possibilities for a
curative operation are usually rather poor. Falsely positive
test findings due to benign biliary tract obstruction hamper a
correct evaluation of the assay results in jaundiced patients
(Jalanko et al., 1984; Haglund et al., 1986; Haglund et al.,
1987).
Carcinoembryonic antigen (CEA) is a 180 kd molecular
weight glycoprotein expressed in embryonic colonic mucosa
and in carcinomas of the gastrointestinal tract (Gold &
Freedman, 1965). Being one of the most extensively studied
tumour marker it has a well established use in monitoring
cancer patients.
CA 242 is a new tumour marker defined by the mono-
clonal antibody C-242 which was obtained by immunising
mice with a human colorectal carcinoma cell line COLO 205
(Lindholm et al., 1985). The structure of the CA 242 antigen
is still unresolved, but there is evidence that it is of carbo-
hydrate nature related to type I chain, but different from that
of CA 19-9 and CA 50 (O. Nilsson, personal communica-
tion). In serum, the CA 242 epitope seems to be located on
the same macromolecular complex as CA 19-9 and CA 50.
This has made it possible to set up a solid-phase immuno-
assay, in which antibodies against CA 50 and CA 242 are
used as 'catcher' and 'detector' antibodies, respectively (Nils-
son et al., 1988).
The aim of the present investigation was to study the CA
242 levels in sera from patients with various digestive tract
malignancies. Special attention was devoted to the com-
parison of the CA 242 concentrations with those of CA 19-9,
CA 50 and CEA.
Materials and methods
Patients
Serum CA 242 levels were measured in 185 patients with
digestive tract malignancies and in 123 patients with benign
digestive tract diseases. Serum CA 19-9, CA 50 and CEA
were also quantitated in these patients. Samples were taken
preoperatively, and in patients with colorectal recurrence at
the time of clinical verification. Patients receiving chemo-
therapy were not included in the study. The diagnosis, based
on histological or cytological data and on clinical and
laboratory findings, were the following:
Colorectal diseases Colorectal carcinoma (19 patients with
Dukes A or B carcinoma, 34 with Dukes C or D carcinoma
and 24 recurrencies); benign diseases (30 patients), including
ulcerative colitis, polyposis coli, diverticulitis and Crohn's
disease.
Gastric diseases Gastric cancer (27 patients); benign gastric
diseases (43 patients), consisting of gastric or duodenal ulcers
and gastritis.
Correspondence: P. Kuusela.
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Biliary tract diseases Cholangiocarcinoma (14 patients);
benign biliary tract diseases (18 patients) consisting of
cholelithiasis with or without jaundice.
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Liver diseases Hepatocellular carcinoma (11 patients);
benign liver diseases (27 patients), including cirrhosis and
acute hepatitis.
Pancreatic diseases Pancreatic cancer (eight patients
operated for cure and 44 patients with locally spread or
advanced disease), acute and chronic pancreatitis (24
patients).
The sera were stored at - 20°C before quantitation.
Assays
Serum CA 242 levels were measured by a dissociation-
enhanced lanthanide fluoroimmunoassay (DELFIA) (Phar-
macia Diagnostics, Uppsala, Sweden). Briefly, aliquots of
patients' sera were incubated for 2 h at 20°C in microwells
coated with purified mouse monoclonal antibodies against
the CA 50 antigen. After washes the wells were treated for
1 h with purified anti-CA-242 monoclonal antibodies com-
plexed with europium chelate (Pharmacia). The bound
europium was finally quantitated after washings by adding
commercial scintillation solution (LKB/Wallac, Turku, Fin-
land) and by counting the wells in an 1230 ArcusT
Fluorometer (LKB/Wallac). An upper limit of normal of
20 U ml-', corresponding to the 99.4th percentile of healthy
blood donors, has been recommended for the assay (Nilsson
et al., 1988).
CA 50, CA 19-9 and CEA were quantitated by commer-
cially available solid phase radioimmunoassays (Pharmacia
Diagnostics, Uppsala, Sweden, and Abbot-Diagnostics,
Chicago, IL, USA, respectively). The cut-off values of
17 U ml-', 37 U ml- ' and 3 ng ml- ', respectively, were used.
For the comparison of various tumour markers, cut-off
values representing the mean concentration + 2 standard
deviations (s.d.) found in patients with relevant benign
diseases were determined, representing a specificity of 95%
for all the different markers.
Results
CA 242 in colorectal diseases
In patients with primary colorectal cancer, elevated CA 242
values (>20 U ml-') were found in 29 out of 53 patients
(55%; median 23Uml-'; range: 3-22100Uml-') (Table I;
Figure 1). High values were seen in 59% of patients with
.'.
.1-4 :: 1.
.". -j
iom,
1
It.
;' i'
. #
.. iw
0
57
9-I
* Up I a -t .:. .A.j
Figure 1 Serum concentrations of CA 242 in patients with
various benign (0) and malignant (0) digestive tract diseases.
The cut-off value for CA 242 (20 U ml-') is indicated as a dashed
line.
advanced disease (Dukes C and D), but also in nine out of
19 (47%) ofpatients with localised cancers (Dukes A and B).
A slightly elevated CA 242 value (up to 41 U ml-') was
found in three out of 29 patients (10%) with benign colorec-
tal diseases. Forty-two per cent of the cancer patients had a
CA 242 level higher than any patient with benign colorectal
disease.
Recurrence of previously operated colorectal carcinoma
caused an elevation of CA 242 in 54% of the patients
(median 22Uml1'; range: 3-1180Uml-'), determined at
the time of clinical verification of the recurrence (Figure 1).
Follow-up with CA 242 was not performed in patients with
colorectal cancer.
CA 242 in gastric diseases
The CA 242 level was elevated in 12 out of 27 patients with
gastric cancer (44%; median 13 U ml-'; range: 3-2610 U
ml-'), whereas benign gastric diseases were associated with
an increased concentration in three out of 43 patients (7%;
median 3 U ml'; range: 3-125 Uml') (Table I; Figure 1).
Six out of 27 patients with gastric cancer (22%) had a value
higher than any patient with benign gastric diseases.
Table I Comparison of CA 242, CA 19-9, CA 50 and CEA, using the recommended
cut-off levels
CA 242 CA 19-9 CA 50 CEA
>2OUml-' >37Uml-' >17Uml-' >3ngml-'
Colorectal diseases
(N = 53; n = 29)
Sensitivity Dukes A-B 47 16 26 32
Dukes C-D 59 44 47 71
Total 55 34 40 57
Specificity 90 100 97 83
Gastric diseases
(N = 27; n = 43)
Sensitivity 44 48 52 41
Specificity 93 100 81 86
Liver diseases
(N=ll; n=27)
Sensitivity 0 9 55 45
Specificity 93 93 56 83
Pancreatic and biliary
diseases
(N = 66; n = 42)
Sensitivity 68 76 73 59
Specificity 95 74 67 79
N = number of patients with cancer. n = number of patients with relevant benign
disease.
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CA 242 in liver diseases
None of the 11 patients with liver cancer had a CA 242 level
above the cut-off value of 20 U ml-', whereas two out of 27
patients with benign hepatic diseases (7%) had an elevated
serum value (up to 40 U ml-') (Table I; Figure 1).
CA 242 in pancreatic and biliary diseases
An elevated serum CA 242 concentration was found in 68%
of 66 patients with pancreatic and biliary cancer (median
93 U ml'; range: 3-84000 U ml-') (Table I; Figure 1). The
highest values were seen in patients with advanced tumours,
but also four out of eight patients with a resectable pan-
creatic tumour had an elevated marker level. Slightly elevated
values (up to 27 U ml-') were found in two out of 42
patients with benign pancreatic and biliary diseases (5%).
Sixty-one per cent of the patients with pancreatic cancer had
a marker level higher than any patient with benign
pancreatico-biliary diseases.
Comparison ofCA 242 with CA 19-9, CA 50 and CEA
The CA 242 levels correlated well with those of CA 19-9 and
CA 50 in various digestive tract diseases. The correlation
coefficients (r2-values) varied between 0.69 and 0.96 (Table
II). A poor overall correlation was found between CA 242
and CEA (Table II), with the exception of gastric diseases, in
which a correlation coefficient of 0.89 was found.
In Table I, CA 242 is compared with CA 19-9, CA 50 and
CEA using the recommended cut-off values for each marker.
For comparison ofthese markers at the same specificity level,
cut-off limits for each marker representing the mean + 2 s.d.
of values found in relevant benign diseases were determined
(Table III).
Table II Correlation of CA 242 values with the serum levels of CA
19-9, CA 50 and CEA in benign and malignant digestive tract
diseases
Correlation coefficientsa
CA 242 vs CA 242 vs CA 242 vs
CA 19-9 CA 50 CEA
Colorectal diseases 0.92 0.92 0.02
Gastric diseases 0.78 0.69 0.89
Pancreatic and biliary 0.95 0.89 0
diseases
Liver diseases 0.89 0.81 0.04
a2r-values (linear regression).
Colorectal diseases Using the recommended cut-off levels,
CA 242 and CEA had similar sensitivities (55% and 57%,
respectively) and specificities (90% and 83%, respectively) for
colorectal cancer (Table I). The sensitivities of CA 19-9
(34%) and CA 50 (40%) were lower, but the specificities
higher (100% and 97%, respectively) (Table I). CA 242 had a
47% sensitivity for local tumours (Dukes A and B), com-
pared with 32% for CEA. In Dukes C-D tumours the sensi-
tivity of CEA was highest (71%). Elevated values of both CA
242 and CEA were found in 40% of the cancer patients
(Table IV). The combination of an elevated CA 242 level and
a normal CEA was seen in 15% (8/53) of these patients,
while the percentage for the opposite combination was 17%
(9/53). Elevation of either CA 242 or CEA was seen in 72%
of the patients (Table IV).
Using the cut-off values based on benign colorectal
diseases, CA 242, CA 19-9 and CA 50 were positive in
31-43% of the patients with Dukes A and B colorectal
cancer, whereas CEA gave a positive test result only in 11%
of the patients (Table III). In patients with Dukes C and D
Table III Comparison of CA 242, CA 19-9, CA 50 and CEA in digestive tract diseases, using
cut-off levels representing the mean + 2 s.d. of relevant benign diseases
CA 242 CA 19-9 CA 50 CEA
Colorectal diseases >29 Uml-' >21 U ml-' > 13 U ml-' >9 ngml'
(N =53; n =29)
Sensitivity Dukes A-B 31 38 43 11
Dukes C-D 53 47 47 56
Total 45 43 45 40
Gastric diseases >47 U ml-' > 12 U ml-' > 103 U ml-' >5 ngml'
(N = 27; n = 43)
Sensitivity 30 67 30 37
Liver diseases >27 Uml-' > 51 U ml-' >70 U ml-' >4ngml'
(N=ll; n=27)
Sensitivity 0 9 9 27
Pancreatic and biliary >20 Uml-' > 155 Uml-' > 145 U ml-' >24ngml-'
diseases
(N = 66; n = 42)
Sensitivity 68 61 46 17
N = number of patients with cancer. n = number of patients with relevant benign disease.
Table IV Comparison of the CA 242 and CEA assays in colorectal diseases
CA 242 and/or Both CA 242 and
CA 242 positive CEA positive CEA positive CEA positive %
Sensitivity for primary 55 57 72 40
colorectal cancer (N = 53)
Dukes A-B (n = 19) 47 32 47 32
Dukes C-D (N = 34) 59 71 85 44
Specificity (n = 29) 90 83 79 93
Sensitivity for recurrent 54 83 88 50
colorectal carcinoma (N = 24)
Cut-off values: CA 242: 20 Uml-'; CEA 3 ngml-'. N = number of patients with cancer. n = number of
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colorectal cancer the markers were positive in about half of
the patients (47-56%).
In patients with recurrent colorectal cancer, CEA was
elevated (>3 ng ml-') in 83%, compared with 42-54% for
the other markers. When the cut-off values based on benign
colorectal diseases were used, the percentage of elevated
values (46%) was similar for all markers (data not shown).
Gastric diseases In gastric diseases, all markers had a
similar sensitivity (41-52%) using the recommended cut-off
values. However, CA 19-9 had the highest specificity (Table
I). Therefore, using cut-off levels based on benign diseases,
CA 19-9 was positive in 67% of patients with gastric cancer,
whereas other assays showed an elevated marker level in only
30-37% of the patients (Table III).
Liver diseases CA 50 and CEA were elevated in about half
of the patients with liver cancer, whereas only one of 11
patients had an elevated CA 19-9 value, and none of the
patients had a CA 242 value above the recommended cut-off
level (Table I). However, CA 50 and CEA were elevated also
in many patients with benign liver diseases (44% and 17%,
respectively) (Table I).
Using the cut-off levels based on benign liver diseases, all
new tests showed very low sensitivities (0-9%) for liver
cancer. CEA was elevated in 27% of these patients (Table
III).
Pancreatic andbiliary diseases The sensitivities of all marker
tests for pancreatic and biliary cancer were higher than for
other digestive tract carcinomas (59-76%) (Table I). CA
19-9 and CA 50 had slightly higher sensitivities than CA 242,
but CA 242 had a higher specificity than the other markers
(Table I).
Using cut-off levels based on benign pancreatic and biliary
diseases, CA 242 and CA 19-9 had clearly higher sensitivities
(68% and 61%, respectively) than CA 50 and CEA (46%
and 17%, respectively) (Table III).
Discussion
CA 242 was elevated in a high percentage of sera from
patients with colorectal, pancreatic and biliary tract cancers.
This could be expected considering that the serum levels of
this new tumour correlated well with those of CA 19-9 and
CA 50, which both are well documented markers for diges-
tive tract malignancies (DelVillano et al., 1983; Holmgren et
al., 1984; Jalanko et al., 1984; Kuusela et al., 1984; Bruhn et
al., 1985; Chan et al., 1985; Paganuzzi et al., 1985; Haglund
et al., 1986; Haglund et al., 1987; Kuusela et al., 1987). On
the other hand, low correlation coefficients indicated that the
CA 242 test measures something else than the CEA assay.
An advantage of CA 242 was a low proportion of elevated
marker levels in patients with benign digestive tract diseases.
This was especially seen in patients with benign extrahepatic
cholestasis, which is a frequent cause of elevated CA 19-9,
CA 50 and CEA values (Carr-Locke, 1980; Haglund et al.,
1986, 1987) and in patients with benign liver diseases, which
frequently cause elevation of CA 50 and CEA (Haglund et
al., 1986, 1987).
When reporting results of tumour markers, the use of
cut-off values recommended by the manufacturers makes it
possible to compare the figures with those of other
laboratories. However, there always are differences in patient
materials, and the cut-off levels of various markers may be
settled in different ways. Therefore, when comparing different
tumour markers, it is essential to measure the serum concen-
trations of the same patient material and to compare the
sensitivities at a fixed specificity level. In this study, we set
the cut-off values for each type of cancer as the mean plus
two standard deviations of the marker levels found in
patients with relevant benign diseases.
Elevated values in a part of the patients with benign
diseases usually cause an increase of the cut-off levels com-
pared with those based on healthy blood donors, i.e. the
recommended cut-off levels. However, in benign colorectal
and gastric diseases the mean + 2 s.d. levels for CA 19-9 are
lower (21 U ml' and 12 U ml', respectively) than the
recommended cut-off level of 37 U ml. The same is true for
CA 50 in colorectal diseases. Interestingly, the mean + 2 s.d.
level for CA 242 in benign pancreatic and biliary diseases is
similar to the recommended upper limit of normal, whereas
contrarily the cut-off levels of CA 19-9, CA 50 and CEA
markedly increase, especially in patients with extrahepatic
cholestasis.
Using the recommended cut-off levels, CA 242 detected
more Dukes A and B carcinomas than CEA (47% vs 32%),
whereas CEA more often was elevated in advanced car-
cinomas. An elevated level of both or either of the markers
increased the sensitivity to 72% (from 55% and 57%, respec-
tively) with a decrease of the specificity from 90% and 83%
for CA 242 and CEA, respectively, to 79%. The combination
of the two markers will thus gain 15-17% in primary diag-
nosis of colorectal cancer, with a loose of 4-11% in
specificity.
Using cut-offlevels based on benign colorectal diseases, the
new markers were more sensitive than CEA in detecting
primary localised colorectal cancers. CA 50, CA 19-9 and CA
242 detected 7 (44%), 6 (38%) and 5 (31%), respectively, out
of 16 Dukes A or B colorectal cancer patients, who had
normal CEA levels. An elevation of CEA never occurred
without a concomitant elevation of the other markers. In
primary Dukes C and D colorectal carcinomas and in
patients with recurrencies of colorectal cancer there was no
significant difference between the markers.
Pancreatic and extrahepatic biliary cancer mostly cause
similar clinical signs and symptoms, and both benign pan-
creatic diseases and benign and malignant obstruction of the
bile duct may be differential diagnostic problems in the diag-
nosis of pancreatic cancer. Therefore, in this study these
diseases are evaluated together.
In pancreatic and biliary diseases the sensitivity of CA 242
was somewhat lower (68%) than that of CA 19-9 (76%) and
CA 50 (73%), but the specificity was clearly higher. Elevated
CA 19-9 and CA 50 values are frequently seen in benign
pancreatic diseases, and especially in patients with extra-
hepatic cholestasis (Jalanko et al., 1984; Haglund et al., 1986,
1987). In these patients CA 242 is rarely elevated. Determin-
ing the threshold levels on the basis ofbenign diseases caused
a marked elevation of cut-off values for CA 19-9 and CA 50
(155 U ml-' and 145 U ml-', respectively), whereas the cut-off
value for CA 242 remains as low as 20 U mlV'. This indicated
that CA 242 might be more effective in detecting pancreatic
and biliary tract cancer. The sensitivities of CA 19-9 and CA
50 fall to 61% and 46%, respectively, whereas that of CA 242
remained unchanged (68%). A more marked decrease of the
sensitivities of CA 19-9 and CA 50 might have been expected.
One explanation might be the fact that patients included in
this study mainly had disseminated pancreatic or biliary tract
cancer associated with very high serum concentrations well
above the cut-off levels. CEA has a lower sensitivity and
specificity than the other markers in these diseases.
Our material included eight patients with small resectable
pancreatic tumours. Elevated values ofall three markers were
seen in half of the patients, whereas one patient had slightly
elevated CA 19-9 and CA 50 values, but a normal CA 242
level. Studies including a larger number of small localised
cancers would provide further information, whether there are
any differences between the markers in detecting resectable
pancreatic cancers.
In all carcinoma groups there were patients with rather
large tumours and a normal CA 242 level and vice versa.
However, mostly the highest serum values were found in
patients with advanced disease. Therefore, there seems to be
a correlation between the tumour burden and the serum level
of CA 242.
The results of this study show that the expression of CA
242 is rather similar to the previously reported tumour
markers, CA 19-9 and CA 50. The lower frequency of640 P. KUUSELA et al.
elevated values in benign diseases, especially in patients with
jaundice, compared with CA 19-9 and CA 50, is a clear
advantage. Evaluation of larger patient materials and studies
on the utility of CA 242 in the follow-up of operated patients
with pancreatic cancer, are needed to show a possible clinical
advantage of CA 242. The sensitivity of the CA 242 test for
gastric carcinoma is too low to be clinically useful. The
sensitivity for localised colorectal carcinoma is also low, only
47%, but still higher than that of CEA. However, the benefit
in this material of combining CEA and CA 242 encourages
further studies also in this group of cancer patients. In this
material 54% on the patients with recurrence of colorectal
carcinoma had an elevated CA 242 serum level at the time of
verification ofthe recurrence. Clinically it would, however, be
of importance to know whether the marker level elevates
prior to clinical signs and symptoms of recurrence, thus
providing a lead time compared to conventional diagnostic
methods. A follow-up study with CA 242 in patients with
colorectal carcinoma is now in progress. As a conclusion, CA
242 is a promising new tumour marker and may have a place
in clinical diagnosis of digestive tract malignancies.
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